1. Home
  2. FEMY vs NRSN Comparison

FEMY vs NRSN Comparison

Compare FEMY & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FEMY
  • NRSN
  • Stock Information
  • Founded
  • FEMY 2004
  • NRSN 2017
  • Country
  • FEMY United States
  • NRSN Israel
  • Employees
  • FEMY N/A
  • NRSN N/A
  • Industry
  • FEMY Medical/Dental Instruments
  • NRSN Biotechnology: Pharmaceutical Preparations
  • Sector
  • FEMY Health Care
  • NRSN Health Care
  • Exchange
  • FEMY Nasdaq
  • NRSN Nasdaq
  • Market Cap
  • FEMY 30.2M
  • NRSN 29.8M
  • IPO Year
  • FEMY 2021
  • NRSN 2021
  • Fundamental
  • Price
  • FEMY $0.94
  • NRSN $0.96
  • Analyst Decision
  • FEMY Strong Buy
  • NRSN Buy
  • Analyst Count
  • FEMY 3
  • NRSN 2
  • Target Price
  • FEMY $7.33
  • NRSN $14.00
  • AVG Volume (30 Days)
  • FEMY 15.7M
  • NRSN 196.9K
  • Earning Date
  • FEMY 11-10-2025
  • NRSN 12-17-2025
  • Dividend Yield
  • FEMY N/A
  • NRSN N/A
  • EPS Growth
  • FEMY N/A
  • NRSN N/A
  • EPS
  • FEMY N/A
  • NRSN N/A
  • Revenue
  • FEMY $1,887,016.00
  • NRSN N/A
  • Revenue This Year
  • FEMY $81.63
  • NRSN N/A
  • Revenue Next Year
  • FEMY $158.53
  • NRSN N/A
  • P/E Ratio
  • FEMY N/A
  • NRSN N/A
  • Revenue Growth
  • FEMY 98.61
  • NRSN N/A
  • 52 Week Low
  • FEMY $0.31
  • NRSN $0.80
  • 52 Week High
  • FEMY $1.80
  • NRSN $2.60
  • Technical
  • Relative Strength Index (RSI)
  • FEMY 64.01
  • NRSN 34.75
  • Support Level
  • FEMY $0.61
  • NRSN $0.91
  • Resistance Level
  • FEMY $0.88
  • NRSN $1.14
  • Average True Range (ATR)
  • FEMY 0.14
  • NRSN 0.07
  • MACD
  • FEMY 0.03
  • NRSN -0.02
  • Stochastic Oscillator
  • FEMY 68.28
  • NRSN 19.97

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: